Shimizu H, Uehara Y, Shimomura Y, Negishi M, Kobayashi I, Kobayashi S
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
J Endocrinol Invest. 1991 May;14(5):401-4. doi: 10.1007/BF03349089.
The effect of recombinant human interleukin-1 beta (rhIL-1b) on in vivo insulin secretion was examined in intact and adrenalectomized (ADX) rats under conscious and pentobarbital anesthetized conditions. In conscious rats, rhIL-1b dose-dependently decreased blood glucose levels at 2 h in both groups and significantly inhibited insulin release only at doses of 1 and 10 micrograms/kg in ADX rats. Under pentobarbital anesthesia, rhIL-1b administration decreased blood glucose levels 2 h later in both intact and ADX rats and resulted in severe hypoglycemia in ADX rats. At 2 h later, rhIL-1b significantly suppressed insulin release by pentobarbital injection in both intact and ADX rats. It is concluded that rhIL-1b suppresses in vivo insulin secretion in conscious ADX and anesthetized rats.
在清醒和戊巴比妥麻醉条件下，研究了重组人白细胞介素-1β（rhIL-1b）对完整大鼠和肾上腺切除（ADX）大鼠体内胰岛素分泌的影响。在清醒大鼠中，两组大鼠在2小时时rhIL-1b均剂量依赖性降低血糖水平，且仅在ADX大鼠中，剂量为1和10微克/千克时显著抑制胰岛素释放。在戊巴比妥麻醉下，给予rhIL-1b后2小时，完整大鼠和ADX大鼠的血糖水平均降低，且ADX大鼠出现严重低血糖。2小时后，rhIL-1b显著抑制戊巴比妥注射后完整大鼠和ADX大鼠的胰岛素释放。得出结论：rhIL-1b抑制清醒ADX大鼠和麻醉大鼠体内的胰岛素分泌。
